HIGHLIGHTS
- What: The authors showed that not only the risk of cardiovascular events, but also the hemorrhagic risk was reduced in azithromycin users, and this was irrespective of the type of oral anticoagulant (warfarin or NOACs).
- Who: Tommaso Bucci from the Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK have published the article: Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease, in the Journal: (JOURNAL)
- How: In this study the principal findings are as follows . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.